Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...